STAAR Surgical (NASDAQ:STAA) Upgraded by Wedbush to Outperform Rating

Posted by Francis Steltz on May 14th, 2026

STAAR Surgical (NASDAQ:STAA – Get Free Report) was upgraded by analysts at Wedbush from a “neutral” rating to an “outperform” rating in a report released on Thursday, MarketBeat reports. The firm presently has a $40.00 price objective on the medical instruments supplier’s stock. Wedbush’s price target would indicate a potential upside of 36.05% from the company’s current price.

Several other research analysts also recently commented on the company. Morgan Stanley assumed coverage on STAAR Surgical in a report on Friday, January 16th. They set an “underweight” rating and a $13.00 target price on the stock. Wells Fargo & Company lowered their price objective on STAAR Surgical from $30.75 to $16.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Stifel Nicolaus reduced their target price on STAAR Surgical from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday, March 4th. Jefferies Financial Group decreased their target price on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Finally, Wall Street Zen upgraded shares of STAAR Surgical to a “hold” rating in a report on Saturday, April 11th. Three research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $26.06.

Read Our Latest Analysis on STAAR Surgical

STAAR Surgical Price Performance

STAA opened at $29.40 on Thursday. STAAR Surgical has a fifty-two week low of $15.59 and a fifty-two week high of $30.81. The company’s 50 day moving average price is $22.22 and its two-hundred day moving average price is $22.54. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -18.04 and a beta of 1.20.

STAAR Surgical (NASDAQ:STAA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. The company had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. During the same quarter in the previous year, the business earned ($1.10) earnings per share. STAAR Surgical’s revenue was up 119.6% compared to the same quarter last year. As a group, equities research analysts predict that STAAR Surgical will post -0.03 EPS for the current year.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, Director Broadwood Partners, L.P. acquired 316,017 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were bought at an average cost of $18.61 per share, with a total value of $5,881,076.37. Following the purchase, the director directly owned 16,123,842 shares of the company’s stock, valued at $300,064,699.62. This trade represents a 2.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders bought 670,213 shares of company stock valued at $12,266,249. Company insiders own 39.90% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds have recently added to or reduced their stakes in STAA. New York Life Investment Management LLC bought a new position in shares of STAAR Surgical during the 3rd quarter worth approximately $2,243,000. Alpine Associates Management Inc. bought a new stake in shares of STAAR Surgical in the 3rd quarter valued at $24,535,000. Versor Investments LP acquired a new position in shares of STAAR Surgical during the 3rd quarter valued at $5,708,000. Defender Capital LLC. bought a new position in STAAR Surgical during the fourth quarter worth $15,429,000. Finally, Polar Asset Management Partners Inc. bought a new position in STAAR Surgical during the third quarter worth $3,359,000. 96.70% of the stock is currently owned by institutional investors.

About STAAR Surgical

(Get Free Report)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.